GSK to buy pulmonary hypertension biotech 35Pharma for $950Mnews2026-02-25T09:51:24+00:00February 25th, 2026|Endpoints News|
HHS commits up to $144M to study anti-aging approaches via ARPA-Hnews2026-02-24T20:46:28+00:00February 24th, 2026|Endpoints News|
Novo Nordisk to slash Wegovy list price in half in 2027 news2026-02-24T20:38:01+00:00February 24th, 2026|Endpoints News|
Industry groups lay legal groundwork against pricing demosnews2026-02-24T20:36:25+00:00February 24th, 2026|Endpoints News|
UCLA spinout raises $11M to test microbiome-based weight loss therapynews2026-02-24T19:38:18+00:00February 24th, 2026|Endpoints News|
Can the ACCESS pilot crack a longstanding barrier for startups?news2026-02-24T17:25:06+00:00February 24th, 2026|Endpoints News|
BioMarin fails to find buyer, pulls Roctavian gene therapy off marketnews2026-02-24T16:17:44+00:00February 24th, 2026|Endpoints News|
Patient dies in MacroGenics’ cancer study, FDA puts trial on holdnews2026-02-24T15:40:28+00:00February 24th, 2026|Endpoints News|
Beam Therapeutics’ new PKU program; Protara’s bladder cancer datanews2026-02-24T15:35:10+00:00February 24th, 2026|Endpoints News|
Abcuro drug fails muscle weakness trial, development to continuenews2026-02-24T15:24:47+00:00February 24th, 2026|Endpoints News|
